Don't Treat Ghosts Anti-MRSA Antibiotics in Osteomyelitis Without Identified MRSA

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

365 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-06-23

Study Completion Date

2024-06-23

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Osteomyelitis is described as infection and inflammation of the long bone or bone marrow, often due to an open wound, operation, or invasive trauma.1 It is invasive and involves hematogenous seeding or contiguous spread of the infectious organism

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Antibiotic Use in Facial Fracture Post Injury

NCT04925531

Trauma Injury

RECRUITING

Study to Assess Safety and Clinical Activity of Local MBN-101 in Treatment of Infected Bone Sites

NCT02436876

Bacterial Infection

COMPLETED PHASE2

Ceftriaxone as Home IV for Staph Infections

NCT04141787

Staphylococcal Infections Osteomyelitis CNS Infection +5 more

UNKNOWN PHASE4

Antibiotic Treatment Duration for Non-Surgically-Treated Diabetic Foot Osteomyelitis

NCT02123628

Diabetes Mellitus

COMPLETED PHASE4

Ceftaroline for Treatment of Hematogenously Acquired Staphylococcus Aureus Osteomyelitis in Children

NCT02335905

Hematogenously Acquired Staphylococcus Aureus Osteomyelitis Bone Infection Osteomyelitis

COMPLETED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This disease can be classified by location of infection, extent of spread, chronicity, and source of infection.3,4 Osteomyelitis can be caused by a variety of organisms, most commonly gram-positive staphylococci.

Osteomyelitis is associated with a high rate of relapse, high disease burden, and high health care costs.3 Following confirmation of disease via imaging and histopathologic examination, treatment consists of antibiotic therapy and, often, surgical intervention.3,5,6 Treatment with antibiotic therapy is often administered for 4-6 weeks when surgical intervention is not performed.6 Antibiotic selection should be guided by microbiology and antimicrobial susceptibilities.4 Thirty to sixty percent of osteomyelitis cases are caused by Staphylococcus aureus.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Osteomyelitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

RETROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Anti-MRSA therapy

chart review to determine the clinical outcomes of patients with osteomyelitis who were placed on definitive anti-MRSA treatment, despite no identified MRSA cultures.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Anti-MRSA Antibiotics

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* • Admission to any MHS hospital between April 1, 2017 and April 1, 2023

* \> 18 years of age
* Documented osteomyelitis location of the lower limb via ICD-10 code
* Documented imaging of lower limb osteomyelitis during index admission
* Planned intravenous (IV) antibiotics for at least 4 weeks

Exclusion Criteria

* • IV antibiotics for less than 24 hours inpatient

* Planned surgical intervention documented at admission
* Patients receiving monotherapy with an anti-MRSA agent
* Positive MRSA culture during index admission
* Current outpatient antibiotic use on index admission
* Repeated hospital admission during study period

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No